

1. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: A review. *Semin Oncol* 1996;23:251–275.
2. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. *Cancer J* 2001;7:266–273.
3. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004;64:2634–2638.
4. Klein AP, Beatty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. *Genet Epidemiol* 2002;23:133–149.
5. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
6. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. *Fam Cancer* 2012;11:235–242.
7. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. *J Med Genet* 2005;42:711–719.
8. Kim DH, Crawford B, Ziegler J, et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. *Fam Cancer* 2009;8:153–158.
9. Martin ST, Matsubayashi H, Rogers CD, et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. *Oncogene* 2005;24:3652–3656.
10. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. *Cancer Res* 2002;62:3789–3793.
11. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. *J Natl Cancer Inst* 2003;95:214–221.
12. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:342–346.
13. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res* 1996;56:5360–5364.
14. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. *J Clin Oncol* 2009;27:433–438.
15. Figier A, Irmin L, Geva R, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. *Br J Cancer* 2001;84:478–481.
16. Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. *Cancer* 2012;118:493–499.
17. Cho JH, Bang S, Park SW, et al. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group. *Pancreas* 2008;36:337–340.
18. Ghorzo P, Pensotti V, Fomarin G, et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. *Fam Cancer* 2012;11:41–47.
19. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* 2002;94:1358–1365.
20. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 2002;94:1365–1372.
21. Al-Sukhni W, Rothenmund H, Borgida AE, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. *Hum Genet* 2008;124:271–278.
22. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. *Cancer Genet Cytogenet* 2005;158:119–125.
23. Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study. *JAMA* 1982;247:2798–2802.
24. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. *Cancer Biol Ther* 2009;8:131–135.
25. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nat Genet* 2007;39:162–164.
26. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nat Genet* 2007;39:159–161.
27. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 2007;39:165–167.
28. McInerney NM, Miller N, Rowan A, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. *Breast Cancer Res Treat* 2010;121:203–210.
29. Gunnarsson H, Arason A, Gillanders EM, et al. Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. *J Negat Results Biomed* 2008;7:5.
30. Papi L, Putignano AL, Congregati C, et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy. *Fam Cancer* 2010;9:181–185.
31. Ding YC, Steele L, Chu LH, et al. Germline mutations in PALB2 in African-American breast cancer cases. *Breast Cancer Res Treat* 2011;126:227–230.
32. Zheng Y, Zhang J, Niu Q, et al. Novel germline PALB2 truncating mutations in African American breast cancer patients. *Cancer* 2012;118:1362–1370.
33. Cao AY, Huang J, Hu Z, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. *Breast Cancer Res Treat* 2009;114:457–462.
34. Blanco A, de la Hoya M, Balmaña J, et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. *Breast Cancer Res Treat* 2012;132:307–315.
35. Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. *Fam Cancer* 2009;8:347–353.
36. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. *Cancer Res* 2011;71:2222–2229.
37. Tischkowitz M, Capanu M, Sabbaghian N, et al. Rare germline mutations in PALB2 and breast cancer risk: A population-based study. *Hum Mutat* 2012;33:674–680.
38. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. *Breast Cancer Res* 2007;9:R83.
39. Erkkö H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. *Nature* 2007;446:316–319.
40. Erkkö H, Dowty JC, Nikkilä J, et al. Penetrance analysis of the PALB2c.1592delT founder mutation. *Clin Cancer Res* 2008;14:4667–4671.
41. Sabbaghian N, Kyle R, Hao A, et al. Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma. *Fam Cancer* 2011;10:315–317.
42. Adank MA, van Mil SE, Gille JJ, et al. PALB2 analysis in BRCA2-like families. *Breast Cancer Res Treat* 2011;127:357–362.
43. Tischkowitz M, Sabbaghian N, Ray AM, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. *Prostate* 2008;68:675–678.
44. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009;324:217.
45. Harinck F, Kluij I, van Mil SE, et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. *Eur J Hum Genet* 2012;20:577–579.
46. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010;78:490–494.
47. Stadler ZK, Salo-Mullen E, Sabbaghian N, et al. Germline PALB2 mutation analysis in breast-pancreas cancer families. *J Med Genet* 2011;48:523–525.
48. Peterlongo P, Catucci I, Pasquini G, et al. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. *Breast Cancer Res Treat* 2011;126:825–828.
49. Kanda M, Matthaai H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology* 2012;142:730–733.
50. Remmers N, Bailey JM, Mohr AM, et al. Molecular pathology of early pancreatic cancer. *Cancer Biomark* 2011;9:421–440.
51. Bartsch D, Shevlin DW, Tung WS, et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chromosomes Cancer* 1995;14:189–195.
52. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. *Clin Cancer Res* 2008;14:7151–7157.
53. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer* 2000;87:809–811.
54. Mukherjee B, Delancey JO, Raskin L, et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. *J Natl Cancer Inst* 2012;104:953–956.
55. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: Implications for genetic counseling. *Eur J Hum Genet* 2011;19:472–478.
56. Ghorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. *J Med Genet* 2012;49:164–170.
57. Debnik T, van de Wetering T, Scott R, et al. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. *Eur J Cancer Prev* 2008;17:389–391.
58. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. *Fam Cancer* 2011;10:323–330.
59. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. *Ann Surg* 2002;236:730–737.
60. Lal G, Liu L, Hogg D, et al. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. *Genes Chromosomes Cancer* 2000;27:358–361.
61. Goggins M, Offerhaus GJ, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. *Am J Pathol* 1998;152:1501–1507.
62. Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. *Cancer Res* 2001;61:3136–3144.

63. Lynch HT, Voorhees CJ, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. *Br J Cancer* 1985;52:271–273.
64. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. *Clin Genet* 2009;75:141–149.
65. Geary J, Sasieni P, Houlston R, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). *Fam Cancer* 2008;7:163–172.
66. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 2009;302:1790–1795.
67. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 1999;81:214–218.
68. Vasen HF, Offerhaus GJ, den Hartog Jager FH, et al. The tumor spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. *Int J Cancer* 1990;46:31–34.
69. Gargiulo S, Torrini M, Ollila S, et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. *Fam Cancer* 2009;8:547–553.
70. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. *Clin Gastroenterol Hepatol* 2004;2:252–261.
71. Lowenfels AB, Maisonneuve P, Di Magno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst* 1997;89:442–446.
72. Rebours V, Boutron-Ruault MC, Schnee MF, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. *Am J Gastroenterol* 2008;103:111–119.
73. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. *JAMA* 2001;286:169–170.
74. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. *Gastroenterology* 2000;119:1447–1453.
75. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology* 2004;126:1788–1794.
76. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz–Jeghers syndrome. *Clin Cancer Res* 2006;12:3209–3215.
77. Grützmann R, McFaul C, Bartsch DK, et al. No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. *Cancer Lett* 2004;214:63–68.
78. Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Int J Cancer* 2010;127:1421–1428.
79. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology* 2012;142:796–804.
80. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. *Am J Gastroenterol* 2011;106:946–954.
81. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: A comprehensive strategy of imaging and genetics. *Clin Cancer Res* 2010;16:5028–5037.
82. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. *Gut* 2009;58:1410–1418.
83. Goggins M. Markers of pancreatic cancer: working toward early detection. *Clin Cancer Res* 2011;17:635–637.